
Jeff Elton, ConcertAI CEO (via MassBio)
ConcertAI sings a unicorn tune as the FDA-partnered clinical trials software upstart expands
The crescendo is building at ConcertAI as the artificial intelligence life sciences startup reels in its ensemble to boost clinical study diversity, expand decentralized clinical trials and pile on the real-world data for cancer treatments.
The FDA-partnered upstart raised a $150 million Series C, soaring into unicorn status to a $1.9 billion valuation, to take its tech on a worldwide tour. The current set list of 45 biopharma and contract research organization customers is not enough for the five-year-old Cambridge, MA, company.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters